Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-010089
Filing Date
2025-05-14
Accepted
2025-05-14 06:34:20
Documents
52
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 667947
2 EX-31.1 ex31-1.htm EX-31.1 11505
3 EX-31.2 ex31-2.htm EX-31.2 12287
4 EX-32.1 ex32-1.htm EX-32.1 6810
5 EX-32.2 ex32-2.htm EX-32.2 6992
  Complete submission text file 0001641172-25-010089.txt   4269456

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE kapa-20250331.xsd EX-101.SCH 41499
7 XBRL CALCULATION FILE kapa-20250331_cal.xml EX-101.CAL 29575
8 XBRL DEFINITION FILE kapa-20250331_def.xml EX-101.DEF 158545
9 XBRL LABEL FILE kapa-20250331_lab.xml EX-101.LAB 353174
10 XBRL PRESENTATION FILE kapa-20250331_pre.xml EX-101.PRE 258048
54 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 570821
Mailing Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064
Business Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064 818-404-5541
Kairos Pharma, LTD. (Filer) CIK: 0001962011 (see all company filings)

EIN.: 462993314 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42275 | Film No.: 25942550
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)